PolyPid (PYPD) Competitors

$4.38 +0.16 (+3.79%)

Closing price 04:00 PM Eastern

Extended Trading

$4.38 0.00 (0.00%)

As of 04:10 PM Eastern

PYPD vs. CLPT, RXST, TLSI, SI, and CARL

Should you buy PolyPid stock or one of its competitors? MarketBeat compares PolyPid with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PolyPid include ClearPoint Neuro (CLPT), RxSight (RXST), TriSalus Life Sciences (TLSI), Shoulder Innovations (SI), and Carlsmed (CARL). These companies are all part of the "medical equipment" industry.

How does PolyPid compare to ClearPoint Neuro?

PolyPid (NASDAQ:PYPD) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

PolyPid presently has a consensus target price of $12.25, indicating a potential upside of 179.68%. ClearPoint Neuro has a consensus target price of $18.00, indicating a potential upside of 40.96%. Given PolyPid's stronger consensus rating and higher possible upside, equities analysts clearly believe PolyPid is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

PolyPid has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market.

PolyPid has a net margin of 0.00% compared to ClearPoint Neuro's net margin of -71.57%. ClearPoint Neuro's return on equity of -137.02% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-215.51%	-116.18%
ClearPoint Neuro	-71.57%	-137.02%	-39.46%

ClearPoint Neuro has higher revenue and earnings than PolyPid. ClearPoint Neuro is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
ClearPoint Neuro	$36.97M	10.36	-$25.54M	-$1.01	N/A

In the previous week, PolyPid had 4 more articles in the media than ClearPoint Neuro. MarketBeat recorded 12 mentions for PolyPid and 8 mentions for ClearPoint Neuro. PolyPid's average media sentiment score of 0.52 beat ClearPoint Neuro's score of 0.04 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ClearPoint Neuro	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PolyPid beats ClearPoint Neuro on 9 of the 15 factors compared between the two stocks.

How does PolyPid compare to RxSight?

PolyPid (NASDAQ:PYPD) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

PolyPid has a net margin of 0.00% compared to RxSight's net margin of -36.58%. RxSight's return on equity of -17.01% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-215.51%	-116.18%
RxSight	-36.58%	-17.01%	-15.12%

PolyPid presently has a consensus target price of $12.25, indicating a potential upside of 179.68%. RxSight has a consensus target price of $9.44, indicating a potential upside of 67.75%. Given PolyPid's stronger consensus rating and higher possible upside, equities analysts clearly believe PolyPid is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

PolyPid has higher earnings, but lower revenue than RxSight. RxSight is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
RxSight	$134.48M	1.73	-$38.94M	-$1.13	N/A

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 10.1% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

PolyPid has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, RxSight has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

In the previous week, PolyPid had 7 more articles in the media than RxSight. MarketBeat recorded 12 mentions for PolyPid and 5 mentions for RxSight. PolyPid's average media sentiment score of 0.52 beat RxSight's score of 0.01 indicating that PolyPid is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PolyPid beats RxSight on 10 of the 15 factors compared between the two stocks.

How does PolyPid compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

PolyPid has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -60.85%. TriSalus Life Sciences' return on equity of 0.00% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-60.85%	N/A	-69.91%
PolyPid	N/A	-215.51%	-116.18%

PolyPid has lower revenue, but higher earnings than TriSalus Life Sciences. PolyPid is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	3.42	-$39.23M	-$1.83	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A

TriSalus Life Sciences has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, PolyPid has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

TriSalus Life Sciences currently has a consensus target price of $7.50, indicating a potential upside of 197.62%. PolyPid has a consensus target price of $12.25, indicating a potential upside of 179.68%. Given TriSalus Life Sciences' higher probable upside, analysts clearly believe TriSalus Life Sciences is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
PolyPid	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, PolyPid had 4 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 12 mentions for PolyPid and 8 mentions for TriSalus Life Sciences. PolyPid's average media sentiment score of 0.52 beat TriSalus Life Sciences' score of -0.12 indicating that PolyPid is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
PolyPid	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by insiders. Comparatively, 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

PolyPid beats TriSalus Life Sciences on 9 of the 15 factors compared between the two stocks.

How does PolyPid compare to Shoulder Innovations?

Shoulder Innovations (NYSE:SI) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

PolyPid has a net margin of 0.00% compared to Shoulder Innovations' net margin of -81.78%. Shoulder Innovations' return on equity of -42.98% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shoulder Innovations	-81.78%	-42.98%	-21.25%
PolyPid	N/A	-215.51%	-116.18%

PolyPid has lower revenue, but higher earnings than Shoulder Innovations. PolyPid is trading at a lower price-to-earnings ratio than Shoulder Innovations, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shoulder Innovations	$47.32M	6.81	-$40.36M	-$218.68	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A

Shoulder Innovations currently has a consensus target price of $21.00, indicating a potential upside of 35.05%. PolyPid has a consensus target price of $12.25, indicating a potential upside of 179.68%. Given PolyPid's stronger consensus rating and higher probable upside, analysts clearly believe PolyPid is more favorable than Shoulder Innovations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shoulder Innovations	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
PolyPid	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, PolyPid had 4 more articles in the media than Shoulder Innovations. MarketBeat recorded 12 mentions for PolyPid and 8 mentions for Shoulder Innovations. PolyPid's average media sentiment score of 0.52 beat Shoulder Innovations' score of 0.33 indicating that PolyPid is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shoulder Innovations	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PolyPid	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

26.5% of PolyPid shares are held by institutional investors. 29.0% of Shoulder Innovations shares are held by company insiders. Comparatively, 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

PolyPid beats Shoulder Innovations on 8 of the 13 factors compared between the two stocks.

How does PolyPid compare to Carlsmed?

Carlsmed (NASDAQ:CARL) and PolyPid (NASDAQ:PYPD) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

26.5% of PolyPid shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PolyPid has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.76%	-60.74%	-29.84%
PolyPid	N/A	-215.51%	-116.18%

Carlsmed has higher revenue and earnings than PolyPid. Carlsmed is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	5.79	-$29.63M	-$2.51	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A

In the previous week, PolyPid had 11 more articles in the media than Carlsmed. MarketBeat recorded 12 mentions for PolyPid and 1 mentions for Carlsmed. Carlsmed's average media sentiment score of 0.70 beat PolyPid's score of 0.52 indicating that Carlsmed is being referred to more favorably in the media.

Company	Overall Sentiment
Carlsmed	Positive
PolyPid	Positive

Carlsmed currently has a consensus target price of $19.33, indicating a potential upside of 79.68%. PolyPid has a consensus target price of $12.25, indicating a potential upside of 179.68%. Given PolyPid's stronger consensus rating and higher probable upside, analysts clearly believe PolyPid is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
PolyPid	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

PolyPid beats Carlsmed on 9 of the 14 factors compared between the two stocks.

Get PolyPid News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYPD vs. The Competition

Export

Metric	PolyPid	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$80.53M	$3.06B	$6.34B	$12.38B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	-2.29	18.70	20.90	25.61
Price / Sales	N/A	272.77	549.93	78.79
Price / Cash	N/A	57.78	43.26	56.33
Price / Book	6.35	4.42	9.93	6.96
Net Income	-$34.17M	$72.19M	$3.55B	$333.52M
7 Day Performance	-1.13%	-0.62%	-0.33%	0.45%
1 Month Performance	-0.90%	0.22%	1.34%	4.06%
1 Year Performance	51.03%	46.24%	41.10%	36.24%

PolyPid Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYPD PolyPid	3.3547 of 5 stars	$4.38 +3.8%	$12.25 +179.7%	+55.7%	$80.53M	N/A	N/A	80	News Coverage Earnings Report Short Interest Decrease High Trading Volume
CLPT ClearPoint Neuro	2.0873 of 5 stars	$11.10 -0.7%	$14.50 +30.6%	-14.2%	$335.24M	$36.97M	N/A	110	News Coverage Earnings Report
RXST RxSight	2.7463 of 5 stars	$7.26 -1.6%	$9.78 +34.7%	-58.0%	$305.51M	$134.48M	N/A	220
TLSI TriSalus Life Sciences	2.1476 of 5 stars	$4.61 +3.6%	$7.00 +51.8%	-47.3%	$272.81M	$45.15M	N/A	106	News Coverage Analyst Forecast
SI Shoulder Innovations	3.7227 of 5 stars	$12.95 -0.6%	$20.80 +60.6%	N/A	$270.08M	$47.32M	N/A	61	News Coverage Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYPD) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PolyPid (PYPD) Competitors

PYPD vs. CLPT, RXST, TLSI, SI, and CARL

How does PolyPid compare to ClearPoint Neuro?

Summary

How does PolyPid compare to RxSight?

Summary

How does PolyPid compare to TriSalus Life Sciences?

Summary

How does PolyPid compare to Shoulder Innovations?

Summary

How does PolyPid compare to Carlsmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYPD vs. The Competition

PolyPid Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PolyPid (PYPD) Competitors

PYPD vs. CLPT, RXST, TLSI, SI, and CARL

How does PolyPid compare to ClearPoint Neuro?

Do institutionals and insiders believe in PYPD or CLPT?

Do analysts rate PYPD or CLPT?

Which has more volatility & risk, PYPD or CLPT?

Is PYPD or CLPT more profitable?

Which has better earnings and valuation, PYPD or CLPT?

Does the media favor PYPD or CLPT?

Summary

How does PolyPid compare to RxSight?

Is PYPD or RXST more profitable?

Do analysts rate PYPD or RXST?

Which has better earnings and valuation, PYPD or RXST?

Do institutionals and insiders believe in PYPD or RXST?

Which has more volatility & risk, PYPD or RXST?

Does the media favor PYPD or RXST?

Summary

How does PolyPid compare to TriSalus Life Sciences?

Is TLSI or PYPD more profitable?

Which has stronger valuation and earnings, TLSI or PYPD?

Which has more risk and volatility, TLSI or PYPD?

Do analysts prefer TLSI or PYPD?

Does the media refer more to TLSI or PYPD?

Do insiders & institutionals believe in TLSI or PYPD?

Summary

How does PolyPid compare to Shoulder Innovations?

Is SI or PYPD more profitable?

Which has higher valuation & earnings, SI or PYPD?

Do analysts prefer SI or PYPD?

Does the media favor SI or PYPD?

Do institutionals & insiders believe in SI or PYPD?

Summary

How does PolyPid compare to Carlsmed?

Do institutionals & insiders believe in CARL or PYPD?

Is CARL or PYPD more profitable?

Which has higher valuation & earnings, CARL or PYPD?

Does the media favor CARL or PYPD?

Do analysts prefer CARL or PYPD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYPD vs. The Competition

PolyPid Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools